Lymphoproliferative disorders and chemokines.
Chemokines are low molecular weight cytokines specialized in leukocyte recruitment. Recent studies have shown that tumor cells of hematopoietic and non hematopoietic origin express different chemokine receptors that may be involved in neoplastic cell growth, metastasis and angiogenesis. Human lymphoproliferative disorders arise from the malignant transformation of normal lymphoid cells frozen at discrete maturational stages. Studies performed with acute or chronic lymphoproliferative disorders have shown that CXCR4, the unique receptor for CXCL12, is up-regulated in many B and T cells malignancies and may be involved in metastatic localization of the neoplastic elements. Additional chemokine receptors are expressed in the individual lymphoproliferative disorders, but some of these are often non functional. Here we shall review the state of the art on chemokine receptor expression and function in human lymphoproliferative disorders, stressing the potential value of chemokines receptors as novel therapeutic targets. In this respect, small antagonistic peptides are being produced by pharmaceutical companies and hold great promise for clinical application.
Pistoia
V
V
Laboratory of Oncology, G. Gaslini Institute, Genova, Italy. vitopistoia@ospedale-gaslini.ge.it
Corcione
A
A
Dallegri
F
F
Ottonello
L
L
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000502:physiology; D018925:Chemokines / Q000502:physiology*; D006689:Hodgkin Disease / Q000503:physiopathology; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D009369:Neoplasms / Q000473:pathology / Q000503:physiopathology; D019707:Receptors, Chemokine / Q000187:drug effects / Q000502:physiology*
D000970:Antineoplastic Agents; D018925:Chemokines; D019707:Receptors, Chemokine